Back to Search Start Over

Antimicrobial Stewardship: A Call to Action for Surgeons.

Authors :
Sartelli M
Duane TM
Catena F
Tessier JM
Coccolini F
Kao LS
De Simone B
Labricciosa FM
May AK
Ansaloni L
Mazuski JE
Source :
Surgical infections [Surg Infect (Larchmt)] 2016 Dec; Vol. 17 (6), pp. 625-631. Date of Electronic Publication: 2016 Nov 09.
Publication Year :
2016

Abstract

Despite current antimicrobial stewardship programs (ASPs) being advocated by infectious disease specialists and discussed by national and international policy makers, ASPs coverage remains limited to only certain hospitals as well as specific service lines within hospitals. The ASPs incorporate a variety of strategies to optimize antimicrobial agent use in the hospital, yet the exact set of interventions essential to ASP success remains unknown. Promotion of ASPs across clinical practice is crucial to their success to ensure standardization of antimicrobial agent use within an institution. To effectively accomplish this standardization, providers who actively engage in antimicrobial agent prescribing should participate in the establishment and support of these programs. Hence, surgeons need to play a major role in these collaborations. Surgeons must be aware that judicious antibiotic utilization is an integral part of any stewardship program and necessary to maximize clinical cure and minimize emergence of antimicrobial resistance. The battle against antibiotic resistance should be fought by all healthcare professionals. If surgeons around the world participate in this global fight and demonstrate awareness of the major problem of antimicrobial resistance, they will be pivotal leaders. If surgeons fail to actively engage and use antibiotics judiciously, they will find themselves deprived of the autonomy to treat their patients.<br />Competing Interests: Author Disclosure Statement Dr. Mazuski has received research support from Astra-Zeneca, Bayer, and Merck, and honoraria as an advisory board member, consultant, or speaker from Allergan, Astra-Zeneca, Bayer, and Merck. Dr. Mazuski receives grant support from the National Institutes of Health for collaborative work on an infection control research project. He serves as the President of the Surgical Infection Society without compensation. For the remaining authors, no competing financial interests exist.

Details

Language :
English
ISSN :
1557-8674
Volume :
17
Issue :
6
Database :
MEDLINE
Journal :
Surgical infections
Publication Type :
Academic Journal
Accession number :
27828764
Full Text :
https://doi.org/10.1089/sur.2016.187